Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
61. |
ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. |
Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
62. |
ECCT/20/10/02 | MALCOV Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso (MALCOV) |
Principal Investigator(s) 1. Simon Kariuki 2. Helen Barsosio Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOORTH), (Kisumu county) 2. Kisumu County Referral Hospital. (Kisumu county) 3. Alupe sub-County Hospital, (Busia county) 4. Bondo sub-County Hospital, (Siaya county) 5. Macalder (Nyatike) sub-County Hospital (Migori county) 6. Migori County Teaching and Referral Hospital; (Migori county) |
View |
63. |
ECCT/15/01/05 | In vivo efficacies of AL and DP Open label randomized study evaluating the in vivo efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in children under five years of age in western Kenya. |
Principal Investigator(s) 1. AAron Samuels 2. Simon Kariuki Site(s) in Kenya Siaya District Hospital |
View |
64. |
ECCT/23/04/04 | AGREE Oral antenatal L-citrulline supplementation to reduce adverse pregnancy outcomes: a two-arm, randomized, placebo-controlled multi-site trial in Kenya |
Principal Investigator(s) 1. Hellen Barsosio Site(s) in Kenya 1. Ahero County Hospital (Kisumu county) 2. Alupe sub-county Hospital (Busia county) 3. Siaya County Referral Hospital (Siaya county) |
View |
65. |
ECCT/24/03/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr. Janet Nyawira Oyieko Site(s) in Kenya 1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) |
View |